Neostigmine → Edrophonium
반응식
CN(C([O:6][C:7]1[CH:8]=[CH:9][CH:10]=[C:11]([N+:13]([CH3:16])([CH3:15])[CH3:14])[CH:12]=1)=O)C.[CH3:17][N:18]1[C@@H:22]2[CH2:23][C@@H:24]([O:26][C:27]([CH:29]([C:32]3[CH:33]=[CH:34][CH:35]=[CH:36][CH:37]=3)[CH2:30][OH:31])=[O:28])[CH2:25][C@H:19]1[CH2:20][CH2:21]2>>[CH3:17][CH2:14][N+:13]([C:11]1[CH:10]=[CH:9][CH:8]=[C:7]([OH:6])[CH:12]=1)([CH3:16])[CH3:15].[CH3:17][N:18]1[C@@H:22]2[CH2:23][C@@H:24]([O:26][C:27]([CH:29]([C:32]3[CH:33]=[CH:34][CH:35]=[CH:36][CH:37]=3)[CH2:30][OH:31])=[O:28])[CH2:25][C@H:19]1[CH2:20][CH2:21]2참가 물질
4
실험 절차
Compared to neostigmine (0.043 mg/kg) and atropine (15 mg/kg), the simultaneous administration of edrophonium (0.5 mg/kg) and atropine (74 g/kg) resulted in minimal changes in heart rate or MAP.
출처 및 근거
- ORD 기록
- ord-e47331dd363c4fac9628fdb0ab28cc31
- 출처 데이터셋
- uspto-grants-1990_08